The Canadian Agency for Drugs and Technologies in Health (CADTH) released Issue 8 of its Pharmaceutical Reviews Update announcing updates, including to its Procedure and Submission Guidelines for the CADTH Common Drug Review. The update also announced that effective June 1, 2019, CADTH will no longer review biosimilars through the Common Drug Review (CDR) or the pan-Canadian Oncology Drug Review (pCODR). The decision was made subsequent to an internal review, which included a consultation with the pan-Canadian Pharmaceutical Alliance (pCPA), of the streamlined biosimilar review process launched in February 2018 (reported here). Reasons for the change include the prevention of possible delays to access of new biosimilars and resource allocation at CADTH. Biosimilars should therefore be filed directly with the jurisdictions and pCPA.
Related Publications & Articles
-
Health Canada and the Competition Bureau commit to information sharing to combat false, misleading or deceptive health claims
On March 7, 2024, Health Canada published a Memorandum of Understanding (MOU) with the Competition Bureau (together, Participants) to advance their mutual interests and develop a framework of cooperat...Read More -
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Generic Submissions Under Review list will identify generic filers
On February 23, 2024, Health Canada announced that it will expand the information available on the Generic Submissions Under Review (GSUR) list.Read More